On December 20, Gelonghui reported that Joinn Laboratories (603127.SH) announced that the company or its designated subsidiary intends to sign a partnership agreement (hereinafter referred to as the "Partnership Agreement") with Peking Chongde Yingsheng Investment Management Co., Ltd. (hereinafter referred to as "Chongde Yingsheng"), Peking Huizhifu Technology Development Co., Ltd. (hereinafter referred to as "Huizhifu"), and Peking Guochao Chaoqun Intelligent Technology Co., Ltd. (hereinafter referred to as "Guochao Chaoqun"), to participate in investing in the Beinao Phase I (Peking) Fund (hereinafter referred to as "this Fund"). This Fund plans to focus on brain science as an entry point, mainly investing in fields such as diagnosis and treatment of new generation neurological diseases, providing high-quality technology projects to improve the company's diagnostic and treatment levels. This investment fund aligns with the company's long-term Global Strategy, helps the company integrate quality acquisition projects, broadens industry investment channels, and provides impetus and guarantees for the company to achieve sustainable high-quality development.

The targeted fundraising scale for this Fund is expected to be 90 million yuan (the actual fundraising scale is subject to the final signed Partnership Agreement). The company or its designated subsidiary will subscribe as a limited partner with an investment not exceeding 8 million yuan, accounting for no more than 8.89% of the limited partnership. Due to the needs of the establishment and operation of the Fund, this Fund has already been registered and established by Peking Chongde Yingsheng Investment Management Co., Ltd., Peking Huizhifu Technology Development Co., Ltd., and Peking Guochao Chaoqun Intelligent Technology Co., Ltd., and the business registration procedures have been completed.